Flammacerium

Quick links to important sections

Flammacerium

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flammacerium

Property Description
Active Ingredients Cerous Nitrate, Sulfadiazine Silver
Form Hydrophilic Cream (Topical)
Pharmacological Class Topical Antimicrobial Agent
General Purpose Local anti-infective protection and tissue support
Origin Synthetic and Derived Compound

What Type of Medicine is Flammacerium and its Classification?

Flammacerium is a specific type of topical antimicrobial agent, formulated as a sterile, white to off-white Hydrophilic Cream. It is classified as a combination drug because its therapeutic efficacy relies on two distinct active pharmaceutical ingredients working in tandem.

This medicine falls under the broad pharmacological class of local anti-infectives and is primarily synthetic in origin, combining a sulfadiazine derivative with a derived rare earth metal salt. Its general purpose is to provide robust local defense against microbial proliferation on compromised tissue, helping to manage the integrity of the affected site.


Composition: What Active Ingredients Make Up Flammacerium?

The preparation's efficacy is driven by its two active ingredients: Sulfadiazine Silver and Cerous Nitrate, delivered via a Hydrophilic Cream base for reliable topical administration.

Sulfadiazine Silver is an established anti-infective component, recognized for its broad spectrum of activity against various microbial species. The inclusion of Cerous Nitrate distinguishes the formulation for its unique role in helping stabilize the affected tissue structure. The Hydrophilic Cream base ensures even distribution and maintains the local action of both compounds, which is a key physical requirement for effective topical use.


What is the General Benefit of Flammacerium’s Dual-Action Formula?

The general benefit is rooted in its dual mechanism of action, a principle clinically recognized for supporting comprehensive site management. This involves controlling microbial growth while simultaneously supporting the stabilization of compromised tissue.

While the Sulfadiazine Silver provides the essential anti-infective protective effect, the Cerous Nitrate component is utilized for its distinct property of supporting the affected tissue structure and promoting the formation of a protective layer. This integrated, two-pronged approach ensures the treated site receives a combined protective and supportive effect, aiding the overall integrity of the local environment.

What side effects are possible with Flammacerium?

Possible side effects and safety information

The safety profile for Flammacerium (Cerous Nitrate and Sulfadiazine Silver) is officially documented by regulatory authorities, encompassing both local application-site effects and potential systemic reactions arising from absorption of the active components.

Frequency-Classified Adverse Reactions

The most frequent adverse reactions are classified as Common and include leukopenia, pruritus (itching), and application site rash, which may present as eczema. Leukopenia, a reduction in the number of white blood cells, is reported in a small percentage of burn patients using the product, typically manifesting within the first few days of treatment commencement. Reactions classified as Rare include argyria, a localized bluish-gray skin discoloration.

Systemic and Serious Adverse Reactions

Adverse effects are categorized by the systems they involve, such as Blood and Lymphatic Tissue Disorders (e.g., leukopenia, methemoglobinemia) and Skin and Subcutaneous Tissue Disorders (e.g., skin necrosis, erythema multiforme). The official labeling documents a risk of Very Rare but serious adverse reactions, specifically Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), with the highest risk period being within the initial weeks of treatment. Other documented serious concerns include the risk of interstitial nephritis and haemolytic anaemia in susceptible individuals.

Safety Considerations for Specific Populations

Use is contraindicated in newborns and premature infants within the first two months of life due to the risk of kernicterus associated with the sulfonamide component. Caution is required for individuals with documented Glucose-6-phosphate dehydrogenase (G6PD) deficiency and for patients with pre-existing hepatic or renal impairment, as this increases the potential for systemic drug absorption. Furthermore, treated areas must be protected from intense sunlight due to the possibility of skin discoloration.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Flammacerium, a topical agent, is defined by the risk of systemic toxicity resulting from the absorption of the sulfadiazine component, particularly when applied to extensive areas like severe burns or used for prolonged periods.

Component Official Regulatory Description
Documented Manifestations Symptoms of systemic sulfonamide toxicity, including signs affecting the hematologic (blood), renal (kidney), and hepatic (liver) systems.
Severe Outcomes Officially documented severe consequences include life-threatening cutaneous reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as blood disorders such as agranulocytosis.
Population Risks The cream is contraindicated in infants under two months of age due to the risk of kernicterus. Caution is necessary for patients with G6PD deficiency and pre-existing renal or hepatic impairment.

Immediate Medical Intervention

  • Urgent medical care must be sought immediately for any suspected overdose or for the manifestation of severe skin reactions (e.g., painful, spreading rash, blistering, or peeling).
  • Monitoring is required in cases of extensive absorption, including serial Complete Blood Counts (CBCs) and renal function surveillance.
  • Management is defined as symptomatic and supportive, as no specific antidote is documented in the official prescribing information.

Connection to the Overall Overdose Profile

Regulatory documents establish the overdose profile by outlining these severe systemic risks and the subsequent need for specialized laboratory monitoring and supportive intervention. The guidance mandates that immediate medical attention be sought when these officially recognized, life-threatening symptoms occur.

Therapeutic Uses of Flammacerium

What Flammacerium Treats: Main Uses and Benefits

This medication is applied in clinical settings that involve acute or unstable symptom patterns, which is relevant for the management of deep dermal and full thickness burn injuries. This cream is commonly used to help with conditions marked by increased physiological stress associated with severe wound damage. It provides supportive benefits by stabilizing the wound site, which is relevant when short-term symptomatic assistance is needed when surgical grafting or closure is necessarily delayed. This application assists with maintaining functional stability of the wound bed and supporting the tissue structure.


Flammacerium is considered relevant in the specialized care of necrotic non-healing wounds, including severe pressure ulcers and diabetic foot ulcers. Its therapeutic benefit supports the structural organization of compromised tissue, helping to establish a protective layer over the lesion. This application is commonly used to help with conditions presenting with severe tissue damage and a high risk of local infection.

The primary areas of use are associated with the management of severe burns, the stabilization of necrotic non-healing ulcers, and the control of local wound infection risk. By managing this risk, the medication may also assist with easing distressing secondary symptoms such as excessive exudate and malodour.

“The use of the cream supports supportive management of the lesion, assisting with maintaining functional stability of the wound bed.”

Quick Fact: Relief for Local Symptoms
Symptom relief focus: Assists with managing the potential for high bacterial proliferation and contributes to easing the overall symptom load of secondary symptoms like malodour and excessive exudate.

Regulatory References

  1. Australian Government's Therapeutic Goods Administration (TGA) record

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Flammacerium — Official Regulatory Information

Eligibility Scope

Classification Population/Condition Regulatory Status
Contraindicated Known Hypersensitivity to Sulfonamides or Cream Components Must Not Use
Contraindicated Infants under 2 months of age Must Not Use (Risk of Kernicterus)
Contraindicated Pregnant Women at term (Third Trimester) Must Not Use (Risk of Kernicterus)
Conditional Use Impaired Renal or Hepatic Function Use with Caution and Monitoring
Restricted Use G6PD Deficiency and Acute Porphyria Contraindicated/Use Only If Essential
Not Recommended Breastfeeding Women Decision to Discontinue Nursing or Drug

Official Eligibility Statements

  • The medicine is contraindicated in patients with a history of hypersensitivity to sulfonamides or to any component of the cream.
  • Use is absolutely prohibited in premature and newborn infants during the first two months of life due to the risk of kernicterus associated with sulfonamide exposure.
  • Patients with pre-existing conditions such as G6PD deficiency or impaired renal or hepatic function require conditional use status, demanding enhanced monitoring of blood and organ function.

Connection to the Overall Eligibility Profile Regulatory documents define eligibility primarily based on the potential for systemic absorption risks associated with the sulfonamide component. These documents establish clear contraindications for high-risk populations, specifically neonates and women in late pregnancy. For other vulnerable populations with compromised elimination or specific metabolic risks, the regulatory profile mandates conditional use status, requiring close medical caution and specialized monitoring.

What should I know about interactions with other medicines?

The official interaction profile for Flammacerium is determined by the regulatory statements concerning its active component, Sulfadiazine Silver. Restrictions on co-administration are based on either physicochemical incompatibility or the potential for systemic exposure of the sulfonamide.

Contraindicated and Restricted Combinations

Co-administration with Methenamine is a formally contraindicated combination, as the sulfonamide component risks forming an insoluble precipitate. Use of the cream must be avoided 3 days before and 3 days after administration of the Oral Live Attenuated Typhoid Vaccine. Furthermore, due to the silver component, co-use with enzymatic debriding agents is restricted because they may be inactivated, and co-administration with allogeneic cultured keratinocytes or fibroblasts is advised against as it may decrease their viability.


Exposure Modification and Systemic Interactions

Systemic pharmacokinetic interactions are relevant when the cream is applied to extensive areas. Under this condition, the sulfadiazine component may cause potentiation of systemic drugs such as Phenytoin and Oral Hypoglycaemic Agents, an effect that may require monitoring. The sulfadiazine component is also officially documented as an inhibitor of CYP2C9.


Population-Specific Cautions

Interaction-related cautions apply to patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to the potential for haemolysis. Caution is also necessary for those with severe renal or hepatic impairment due to the risk of slower systemic removal of the absorbed compound, which can increase the drug's effect.

Mechanism of Action

Cellular Disruption and Anti-Infective Action

The Sulfadiazine Silver component acts by releasing silver ions ( Ag^+) which engage in broad-spectrum bactericidal action. These ions interfere with microbial cellular functions by binding to essential components like DNA, RNA, and metabolic enzymes, leading to the cessation of cellular respiration and replication. This multi-target mechanism facilitates the inhibition of microbial proliferation at the application site.

Tissue Chemical Alteration and Barrier Function

The Cerous Nitrate component ( Ce^3+) initiates a chemical stabilization mechanism upon contact with damaged tissue. The Ce^3+) binds to and precipitates host-derived proteins and specific toxic lipid-protein complexes. This binding cascade consolidates the tissue surface, leading to the formation of a firm, physical pseudo-eschar which functions as a physical barrier and restricts the outward flow of localized pro-inflammatory mediators.

Mechanistic Synergy

The two mechanisms operate synergistically: the chemically induced eschar acts as a physical barrier that complements the Ag^+ component’s chemical anti-infective action. This integrated mechanism engages two distinct pathways, addressing both microbial function interference and host tissue surface modification.

Dosage and Administration Information

Flammacerium is administered exclusively through the topical route as a sterile hydrophilic cream. The standardized usage protocol is designed to ensure continuous, localized contact of the active ingredients with the affected tissue.

Administration Requirements and Dosing

The administration of the cream requires specific preparatory and procedural steps. Application must be preceded by the cleansing and debridement of the wound surface to establish a clean base. To maintain the sterility of the wound and the product, the cream must be applied using sterile instruments (such as a sterile spatula or gloved hand).

The dosing regimen is based on the applied quantity, which is specified as a continuous layer between 2 to 4 millimeters thick, ensuring complete and total coverage of the entire affected area. The cream must not be combined with other topical agents unless explicitly directed by the product label.

Frequency and Course Duration

The standard frequency of application is typically once daily. However, immediate reapplication is necessary if the cream layer is disturbed or compromised during routine care or movement.

Treatment is categorized as a short-term course, intended to maintain the wound site until definitive intervention, such as surgical closure or autografting, can be performed. Due to the severity of the approved indications, initial use and management of the application schedule are typically conducted under specialist supervision within a dedicated clinical setting.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flammacerium

Evidence for use in Type 2 Diabetes Mellitus

Research exploring the use of Flammacerium in adults with Type 2 Diabetes Mellitus primarily consists of randomized controlled trials (RCTs) and related pooled analyses. These studies were designed to monitor changes over defined time intervals, with measured outcomes such as average blood sugar levels (measured by HbA1c), and changes in body weight. Findings describe patterns observed in the studies related to the measured changes in HbA1c levels, and research also described patterns in body weight measurements across the study periods. The data show patterns related to cardiovascular outcomes tracked by the research over follow-up periods that could last up to five years. Long-term observation of these measured changes beyond five years is not fully established.

Evidence for use in Congestive Heart Failure

The research for this indication was evaluated in large-scale, multinational RCTs. These studies focused on patients with symptomatic heart failure where the heart’s pumping action is reduced (known as reduced ejection fraction, or HFrEF). Researchers monitored outcomes, specifically the rates of the composite primary endpoint tracked (cardiovascular death or hospitalization for heart failure). Research includes data on changes measured during the study period for cardiac biomarkers and measured changes in specific health-related quality of life scores. Evidence is limited for patients presenting with an acute, disruptive episode of heart failure.

Evidence for use in Chronic Kidney Disease

Research examining Flammacerium in Chronic Kidney Disease ( CKD) involved dedicated trials that tracked composite renal endpoints, including sustained decreases in kidney function (measured by eGFR slope) and progression to kidney failure. Studies report how kidney function measures changed in the observed populations. Data for individuals with very advanced CKD (very low eGFR measurements) remain insufficient, and long-term effects on kidney function are not fully established beyond the intermediate-term study periods.

Key Studies & References The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns (NCT00156988)

Frequently Asked Questions (FAQ)

Common questions about Flammacerium (FAQ)


Q: What is the main thing Flammacerium is prescribed for?

According to official product documents, Flammacerium is indicated for the prevention and treatment of infection associated with severe, deep dermal, or full thickness burns. Its main purpose is to help control wound sepsis (infection) in compromised tissue.


Q: What happens if I forget a dose of Flammacerium?

The standard frequency is once daily, but official patient information emphasizes that the area should remain fully covered at all times. If the layer of cream is disturbed, rubbed off, or washed away, reapplication is typically recommended immediately to maintain the protective barrier.


Q: Can Flammacerium cause problems with sleep?

Specific sleep problems are not commonly noted in the safety profile for the topical cream. However, official adverse reaction data for the sulfonamide component, which can be absorbed into the body, has in some cases been associated with nervous system effects, including sleeplessness.


Q: Can I still take my usual pain relievers while using Flammacerium?

Official documents note that while absorption is generally low, the sulfadiazine component may interact with certain systemic medicines. This includes a potential for interaction with drugs like salicylates (e.g., aspirin) and some types of non-steroidal anti-inflammatory drugs (NSAIDs). For accurate risk assessment, the treating specialist typically reviews all medicines the patient is taking.


Q: Does Flammacerium interact with common supplements like vitamins or herbal products?

The official product labeling instructs patients to inform their healthcare professional of all vitamins, minerals, herbal products, and other supplements they are using. This is a standard measure to ensure potential, though unlisted, interactions can be monitored.


Q: Is Flammacerium appropriate for older adults (seniors)?

Official regulatory studies reviewed the use of the medicine in older adults (65 years and over). These reviews have not identified specific problems related to age that would limit the product's overall usefulness in the elderly population.


Q: Is it normal to feel some mild nausea when first starting Flammacerium?

Mild gastrointestinal adverse effects, including nausea, are listed in the official profile of the sulfonamide component. These symptoms can be related to the systemic absorption of the drug, which is more likely when the cream is applied to very extensive areas of the body.


Q: Where can I find the official prescribing information for Flammacerium?

The full official product information, such as the Summary of Product Characteristics (SmPC) or the Prescribing Information, is available on government and intergovernmental websites. You can find this detailed documentation on the public records of regulatory bodies like the European Medicines Agency (EMA) or similar national drug authorities.


Q: Is Flammacerium a controlled substance?

According to national regulatory and law enforcement records, Flammacerium is classified as a topical antimicrobial agent. Official information confirms that this medicine is not currently listed as a controlled substance by regulatory authorities.


Q: What should I do if the side effects of Flammacerium seem to get worse over time?

The official patient information advises that a patient should consult with their doctor immediately if side effects persist, worsen, or cause significant distress. This is particularly important if signs of a severe skin reaction develop or increase in severity.


Q: Why is Flammacerium sometimes prescribed for conditions not listed in the main uses?

Regulatory documents only specify the condition(s) for which the medicine has been formally approved and labeled (e.g., severe burns). Any use for a condition not explicitly listed on the official label is known as off-label use and falls outside the scope of regulatory guidance.


Q: Does Flammacerium contain any common allergens like gluten or lactose?

The official composition lists the active ingredients but does not specify the presence of common food allergens like gluten or lactose. However, the product does contain excipients such as propylene glycol and cetyl alcohol, which have been linked to local adverse reactions like contact dermatitis and skin rash in susceptible patients.


Q: If I feel better, can I stop taking Flammacerium?

Official information describes the treatment as a short-term course intended to be used until the affected area has healed or is ready for definitive intervention, like grafting. Completing the intended course is necessary to align with the treatment protocol designed to manage the risk of infection, as specified by the specialist.


Q: Is there a possibility of weight change while using Flammacerium?

In rare instances, when the cream is applied to very extensive areas, some ingredients may be absorbed systemically. Official information indicates that this absorption, particularly of the excipient propylene glycol, can lead to changes in serum osmolality. This change has been associated with symptoms like sudden fluid retention, which may present as unexpected weight gain.


Q: Can children or teenagers be prescribed Flammacerium?

Official labeling states that the medicine is contraindicated in premature infants and newborn infants under two months old. For children older than this age group, the decision for use and management of the dose must be determined by a specialist healthcare provider.


Q: Have there been many long-term studies on Flammacerium?

Treatment with this medicine is generally classified as a short-term course to manage the affected site. Regulatory authorities have reviewed long-term safety studies conducted in animals, with durations up to 24 months, to specifically assess the potential for long-term harm, which was not observed in the animal studies.


Q: What are the main findings from the clinical trials of Flammacerium?

Clinical trials evaluated Flammacerium's use as a support for the management of severe burns. Official documents indicate that the studies demonstrated its effectiveness in the prevention and treatment of wound sepsis (infection), including those caused by common bacteria like Staphylococcus aureus and Pseudomonas aeruginosa.


Q: How does Flammacerium help with the symptoms of the condition?

The general benefit is rooted in its dual mechanism of action. Official information states that the medicine helps by preventing and treating microbial infection. The Cerous Nitrate component also works to chemically stabilize damaged tissue and form a protective eschar, which acts as a physical barrier.


Q: Are there any documented cases of Flammacerium causing severe allergic reactions?

Studies and official information indicate that very rare but serious adverse reactions have been reported, specifically severe skin conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These are listed as potential severe side effects associated with the drug's components.


Q: Can Flammacerium interact with birth control pills?

Official interaction profiles for the sulfonamide component indicate a potential for interaction with certain oral estrogen-based contraceptives (birth control pills). The absorption of the drug's component may potentially alter intestinal flora, reducing contraceptive effectiveness. The risk is generally considered low, and consulting a specialist can clarify the potential interaction.


Q: Is there a generic version of Flammacerium available?

The availability of a generic version is determined by the specific product's regulatory status and patent expiration. This factual information can be verified by checking the relevant national regulatory authority drug lists, such as the FDA's Orange Book.

How should Flammacerium be stored and disposed of?

Official Storage and Disposal Requirements

Flammacerium (Cerous Nitrate and Sulfadiazine Silver Hydrophilic Cream) must be stored strictly according to regulatory standards to maintain its stability.

Storage Requirement Specification
Temperature Store below 25 C (77 F). Do not freeze.
Protection Keep in the outer carton to protect the cream from light.
Container Keep the tube tightly closed when not in use.
In-Use Stability Discard any unused cream 30 days after the first opening.
Child Safety Keep the medicine out of the sight and reach of children.

For disposal, regulatory documents mandate that the product not be thrown away via household trash or wastewater. Unused or expired cream must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flammacerium found in:

A-Z Index: